Foresite Capital Management IV’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.08M | Sell |
800,399
-1
| -0% | -$9 | 5.72% | 3 |
|
|
2025
Q1 | $8.61M | Buy |
800,400
+384,150
| +92% | +$4.13M | 7.75% | 3 |
|
|
2024
Q4 | $5.33M | Hold |
416,250
| – | – | 4.9% | 3 |
|
|
2024
Q3 | $11.5M | Hold |
416,250
| – | – | 7.51% | 4 |
|
|
2024
Q2 | $12.1M | Hold |
416,250
| – | – | 8.11% | 4 |
|
|
2024
Q1 | $18.6M | Hold |
416,250
| – | – | 9.38% | 5 |
|
|
2023
Q4 | $16.2M | Sell |
416,250
-22,991
| -5% | -$892K | 8.16% | 5 |
|
|
2023
Q3 | $12.9M | Sell |
439,241
-45,759
| -9% | -$1.35M | 7.17% | 6 |
|
|
2023
Q2 | $30.8M | Sell |
485,000
-15,000
| -3% | -$954K | 15.17% | 2 |
|
|
2023
Q1 | $23.6M | Hold |
500,000
| – | – | 12.25% | 3 |
|
|
2022
Q4 | $34.7M | Hold |
500,000
| – | – | 14.82% | 4 |
|
|
2022
Q3 | $73.3M | Sell |
500,000
-164,109
| -25% | -$24.1M | 23.57% | 2 |
|
|
2022
Q2 | $86.6M | Hold |
664,109
| – | – | 23.32% | 2 |
|
|
2022
Q1 | $67.1M | Hold |
664,109
| – | – | 18.77% | 2 |
|
|
2021
Q4 | $103M | Hold |
664,109
| – | – | 21.15% | 2 |
|
|
2021
Q3 | $197M | Hold |
664,109
| – | – | 28.95% | 2 |
|
|
2021
Q2 | $216M | Buy |
+664,109
| New | +$216M | 29.16% | 2 |
|